Helen Y Zou

Helen Y Zou

UNVERIFIED PROFILE

Are you Helen Y Zou?   Register this Author

Register author
Helen Y Zou

Helen Y Zou

Publications by authors named "Helen Y Zou"

Are you Helen Y Zou?   Register this Author

16Publications

899Reads

38Profile Views

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Cancer Discov 2016 Jan 10;6(1):96-107. Epub 2015 Nov 10.

Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/content/early/2015/1
Web Search
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-15-1056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707106PMC
January 2016

Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.

Drug Metab Dispos 2015 Jan 27;43(1):54-62. Epub 2014 Oct 27.

Pharmacokinetics, Dynamics and Metabolism (S.Y., J.L.L., P.V.) and Oncology Research Unit (H.Y.Z., H.W., T.S.), Pfizer Worldwide Research & Development, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.114.061143DOI Listing
January 2015

Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.

J Pharmacol Exp Ther 2014 Oct 29;351(1):67-76. Epub 2014 Jul 29.

Pharmacokinetics, Dynamics and Metabolism (S.Y., J.L.L., P.V.) and Oncology Research Unit (H.Y.Z., H.W., T.S.), Pfizer Worldwide Research & Development, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.114.217141DOI Listing
October 2014

Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.

ACS Chem Biol 2013 May 6;8(5):978-86. Epub 2013 Mar 6.

Oncology Research Unit, Pfizer Worldwide Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/cb400040z
Publisher Site
http://dx.doi.org/10.1021/cb400040zDOI Listing
May 2013

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

J Pharmacol Exp Ther 2012 Mar 30;340(3):549-57. Epub 2011 Nov 30.

Pharmacokinetics, Dynamics, and Metabolism, La Jolla Laboratories, Pfizer Worldwide Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/content/340/3/549.full.pdf
Web Search
http://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.111.18887
Publisher Site
http://dx.doi.org/10.1124/jpet.111.188870DOI Listing
March 2012

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

Biochemistry 2009 Jun;48(23):5339-49

Pfizer Global Research and Development, La Jolla, Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi900438wDOI Listing
June 2009

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models.

Drug Metab Dispos 2008 Jul 1;36(7):1267-74. Epub 2008 Apr 1.

Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories, Pfizer Global Research and Development, 10777 Science Center Dr., San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.107.019711
Publisher Site
http://dx.doi.org/10.1124/dmd.107.019711DOI Listing
July 2008

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Mol Cancer Ther 2007 Dec;6(12 Pt 1):3314-22

Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, La Jolla, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0365DOI Listing
December 2007